000151303 001__ 151303 000151303 005__ 20251017144615.0 000151303 0247_ $$2doi$$a10.1016/j.nrl.2021.03.003 000151303 0248_ $$2sideral$$a124265 000151303 037__ $$aART-2021-124265 000151303 041__ $$aeng 000151303 100__ $$aCaronna, E. 000151303 245__ $$aSafety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications [Seguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras] 000151303 260__ $$c2021 000151303 5060_ $$aAccess copy available to the general public$$fUnrestricted 000151303 5203_ $$aBackground and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19. 000151303 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es 000151303 590__ $$a5.486$$b2021 000151303 591__ $$aCLINICAL NEUROLOGY$$b46 / 212 = 0.217$$c2021$$dQ1$$eT1 000151303 592__ $$a0.55$$b2021 000151303 593__ $$aNeurology (clinical)$$c2021$$dQ2 000151303 593__ $$aMedicine (miscellaneous)$$c2021$$dQ2 000151303 594__ $$a4.7$$b2021 000151303 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000151303 700__ $$aJosé Gallardo, V. 000151303 700__ $$aAlpuente, A. 000151303 700__ $$aTorres-Ferrus, M. 000151303 700__ $$aSánchez-Mateo, N.M. 000151303 700__ $$aViguera-Romero, J. 000151303 700__ $$aLópez-Veloso, A.C. 000151303 700__ $$aLópez-Bravo, A. 000151303 700__ $$aGago-Veiga, A.B. 000151303 700__ $$aIrimia Sieira, P. 000151303 700__ $$aPorta-Etessam, J. 000151303 700__ $$0(orcid)0000-0001-5139-6031$$aSantos-Lasaosa, S.$$uUniversidad de Zaragoza 000151303 700__ $$aPozo-Rosich, P. 000151303 700__ $$aSpanish, CGRP-COVID, Study, Group 000151303 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000151303 773__ $$g36 (2021), 611-617$$pNeurología (Barc.)$$tNeurología (Barcelona)$$x0213-4853 000151303 8564_ $$s274672$$uhttps://zaguan.unizar.es/record/151303/files/texto_completo.pdf$$yVersión publicada 000151303 8564_ $$s2058833$$uhttps://zaguan.unizar.es/record/151303/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000151303 909CO $$ooai:zaguan.unizar.es:151303$$particulos$$pdriver 000151303 951__ $$a2025-10-17-14:19:08 000151303 980__ $$aARTICLE